

JC10 Rec'd PCT/PTO 06 MAY 2005

#3 PC1

PATENT

ATTORNEY DOCKET NUMBER: 50125/101001

Certificate of Mailing: Date of Deposit: May 4, 2005

I hereby certify under 37 C.F.R. § 1.8(a) that this correspondence is being deposited with the United States Postal Service as **first class mail** with sufficient postage on the date indicated above and is addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Colleen Coyne

Printed name of person mailing correspondence

Colleen Coyne

Signature of person mailing correspondence

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Ingeborg Dreher et al.	Art Unit:	Not yet assigned
Serial No.:	10/530,987	Examiner:	Not yet assigned
Filed:	April 12, 2005	Customer No.:	21559
Title:	ANTAGONISTS IL-15		

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Applicants submit the references listed on the enclosed Form PTO-1449, copies of which are enclosed, with the exception of U.S. patents and U.S. patent application publications.


Submission of this statement is not a representation that a search has been made, nor is the inclusion of information in this statement an admission that the information is material to patentability.

This statement is being filed within three months of the filing date of the application.

If there are any charges or any credits, please apply them to Deposit Account No. 03-2095.

Respectfully submitted,


Date: 4 May 2005



Karen L. Elbing, Ph.D.
Reg. No. 35,238

Clark & Elbing LLP
101 Federal Street
Boston, MA 02110
Telephone: 617-428-0200
Facsimile: 617-428-7045

F:\50125\50125.101001 Information Disclosure Statement.doc

Sheet 1 of 3

SUBSTITUTE FORM PTO-1449 (MODIFIED) INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 C.F.R. § 1.98(b))	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	50125/101001
		Serial No.	10/530,987
		Applicant	Ingeborg Dreher et al.
		Filing Date	April 12, 2005
		Group	Not yet assigned
		IDS Filed	May 4, 2005

U.S. PATENT DOCUMENTS						
Examiner's Initials	Document Number	Publication Date	Patentee or Applicant	Class	Subclass	Filing Date (If Appropriate)
	5,750,825	05/12/98	Yazaki et al.			
	5,698,765	12/16/97	Mak			
	5,625,122	04/29/97	Mak			
	5,583,278	12/10/96	Alt et al.			
	4,736,866	04/12/88	Leder et al.			
FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION						
Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)
	WO 01/32855	05/10/01	WIPO			
	WO 98/36052	08/20/98	WIPO			
	WO 97/41232	11/06/97	WIPO			
	WO 97/11689	04/03/97	WIPO			Abstract
	WO 96/26274	08/29/96	WIPO			
	EP 0 944 398 B1	04/07/04	Europe			
	EP 0 889 723 B1	06/05/02	Europe			Claims
	EP 0 916 336 A1	05/19/99	Europe			
	DE 19625049 A1	01/02/98	Germany			No
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)						
	Behr et al., "Efficient gene transfer into mammalian primary endocrine cells with lipopolyamine-coated DNA," <i>Proc. Natl. Acad. Sci. USA</i> 86: 6982-6986 (1989).					
	Beveridge et al. "Lymphomas and Lymphoproliferative Lesions Developing Under Cyclosporin Therapy," <i>The Lancet</i> 1:788 (1984).					
	Branden et al., "A peptide nucleic acid- nuclear localization signal fusion that mediates nuclear transport of DNA," <i>Nature BioTechnology</i> 17: 784-787 (1999).					

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

SUBSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	50125/101001
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Serial No.	10/530,987
		Applicant	Ingeborg Dreher et al.
		Filing Date	April 12, 2005
		Group	Not yet assigned
		IDS Filed	May 4, 2005
(37 C.F.R. § 1.98(b))			

	Felgner et al., "Enhanced Gene Delivery and Mechanism Studies with a Novel Series of Cationic Lipid Formulations," <i>The Journal of Biological Chemistry</i> 269: 2550-2561 (1994).
	French et al., "The Molecular and Biochemical Characterization of Mutant Monoclonal Antibodies With Increased Antigen Binding," <i>The Journal Of Immunology</i> 146: 2010-2016 (1991).
	Giri et al., "Utilization of the β and γ chains of the IL-2 receptor by the novel cytokine IL- 15," <i>The EMBO Journal</i> 13: 2822-2830 (1994).
	Gossen et al., "Inducible gene expression systems for higher eukaryotic cells," <i>Biotechnology</i> 5: 516-520 (1994).
	Grabstein et al., "Cloning of a T Cell Growth Factor That Interacts with the β Chain of the Interleukin - 2 Receptor," <i>Science</i> 264: 965-968 (1994).
	Huck et al., "Sequence of a human immunoglobulin gamma 3 heavy chain constant region gene: comparison with the other human C γ genes," <i>Nucleic Acids Research</i> 14:1779-1789 (1986).
	Khromykh, "Replicon-based vectors of positive strand RNA viruses," <i>Current Opinion in Molecular Therapeutics</i> 2: 555-569 (2000).
	Kichler et al., "Influence of Membrane-Active Peptides on Lipospermine/DNA Complex Mediated Gene Transfer," <i>Bioconjugate Chem.</i> 8: 213-221, (1997).
	Kim et al., "Targeting the IL-15 Receptor with an Antagonist IL-15 Mutant/Fc γ 2a Protein Blocks Delayed-Type Hypersensitivity," <i>The Journal of Immunology</i> 160: 5742-5748 (1998).
	Kivisakk et al., "IL-15 mRNA expression is up-regulated in blood and cerebrospinal fluid mononuclear cells in multiple sclerosis (MS)," <i>Clinical and Experimental Immunology</i> 111:193-197 (1998).
	Krawinkel et al., "Comparison of the hinge-coding segments in human immunoglobulin gamma heavy chain genes and the linkage of the gamma 2 and gamma 4 subclass genes," <i>The EMBO Journal</i> 1: 403-407 (1982).
	Lindemann et al., "Versatile Retrovirus Vector Systems for Regulated Gene Expression In Vitro and In Vivo," <i>Molecular Medicine</i> 3 466-476 (1997).
	Mackie et al., "Dose-Related Mechanisms of Immunosuppression Mediated By Murine Anti-CD3 Monoclonal Antibody in Pancreatic Islet Cell Transplantation and Delayed-Type Hypersensitivity," <i>Transplantation</i> 49:1150-1154 (1990).
	Paterson et al., "Variation in IgG1 heavy chain allotype does not contribute to differences in biological activity of two human anti-Rhesus (D) monoclonal antibodies," <i>Immunotechnology</i> 4: 37-47 (1998).
	Penn et al., "The Changing Pattern of Posttransplant Malignancies" <i>Transplantation Proceedings</i> 23: 1101-1103 (1991).
	Pettit et al., "Structure-Function Studies of Interleukin 15 using Site-specific Mutagenesis, Polyethylene Glycol Conjugation, and Homology Modeling," <i>The Journal of Biological Chemistry</i> 272(4): 2312-2318 (1997).
	Pink et al., "Human Immunoglobulin Subclasses-Partial Amino Acid Sequence Of The Constant Region Of A γ 4 Chain," <i>Biochem. J.</i> 117:33-47 (1970).
	Plank et al., "The Influence of Endosome-disruptive Peptides on Gene Transfer Using Synthetic Virus-like Gene Transfer Systems," <i>The Journal of Biological Chemistry</i> 269(17) 12918-12924 (1994).
	Rückert et al., "IL-15-IgG2b fusion protein accelerates and enhances a Th2 but not a Th1 immune response in vivo, while IL-2-IgG2b fusion protein inhibits both," <i>Eur. J. Immunology</i> 28: 3312-3320 (1998).
	Sakai et al., "Interleukin 15 Activity in Rectal Mucosa of Inflammatory Bowel Disease," <i>Gastroenterology</i> 114:1237-1243 (1998).
	Schwartz et al., "Synthetic DNA-compacting peptides derived from human sequence enhance cationic lipid-mediated gene transfer in vitro and in vivo," <i>Gene Therapy</i> 6: 282-292 (1999).

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

SUBSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	50125/101001
		Serial No.	10/530,987
		Applicant	Ingeborg Dreher et al.
		Filing Date	April 12, 2005
		Group	Not yet assigned
		IDS Filed	May 4, 2005
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)			
(37 C.F.R. § 1.98(b))			

	Shlomchik et al., "The role of clonal selection and somatic mutation in autoimmunity," <i>Nature</i> 328: 805-811 (1987).
	Sikorav et al., "Structure of the constant and 3' untranslated regions of the murine Balb/c γ 2a heavy chain messenger RNA," <i>Nucleic Acids Research</i> 8: 3143-3155 (1980).
	Springer et al., "VEGF Gene Delivery to Muscle: Potential Role for Vasculogenesis in Adults," <i>Molecular Cell</i> 2:549-558 (1998).
	Tinubu et al., "Humanized Antibody Directed to the IL-2 Receptor β -Chain Prolongs Primate Cardiac Allograft Survival," <i>The Journal of Immunology</i> 153:4330-4338 (1994).
	Uhlmann et al., "Antisense Oligonucleotides: A New Therapeutic Principle," <i>Chemical Reviews</i> 90:544-584 (1990).
	Wang et al., "The Primary Structure of a Human IgG2 Heavy Chain: Genetic, Evolutionary, and Functional Implications" <i>The Journal of Immunology</i> 125(3) : 1048-1054 (1980).
	Wels et al., "Structural analysis of the murine IgG3 constant region gene," <i>The EMBO Journal</i> 3: 2041-2046 (1984).
	Zheng et al., "IL-2 Receptor-Targeted Cytolytic IL-2/Fc Fusion Protein Treatment Blocks Diabetogenic Autoimmunity in Nonobese Diabetic Mice," <i>The Journal of Immunology</i> 163: 4041-4048 (1999).
	Zhou et al., "DNA transfection mediated by cationic liposomes containing lipopolylysine: characterization and mechanism of action," <i>Biochimica et Biophysica Acta</i> 1189: 195-203 (1994).

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	